Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone.

Mehdi, Ali; Attias, Mikhael; Arakelian, Ani; Piccirillo, Ciriaco A; Szyf, Moshe; Rabbani, Shafaat A

Mehdi, Ali; Attias, Mikhael; Arakelian, Ani; Piccirillo, Ciriaco A; Szyf, Moshe; Rabbani, Shafaat A.

Afiliação

Mehdi A; Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 2B4, Canada.
Attias M; Department of Human Genetics, McGill University, Montreal, QC H3A 2B4, Canada.
Arakelian A; Program in Metabolic Disorders and Complications (MeDiC), Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
Piccirillo CA; Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 2B4, Canada.
Szyf M; Department of Microbiology & Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
Rabbani SA; Program in Infectious Diseases and Immunology in Global Health, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada.

Cancers (Basel) ; 15(1)2022 Dec 22.

Article em En | MEDLINE | ID: mdl-36612044